Results 121 to 130 of about 70,337 (151)
[Consensus document for Severe Asthma. 2025 Update]. [PDF]
Álvarez-Gutiérrez FJ +27 more
europepmc +1 more source
[Stroke prevention in patients with nonvalvular atrial fibrillation.What's new?]. [PDF]
Lobos Bejarano JM, González AM.
europepmc +1 more source
Mexican position paper for the diagnosis and treatment of cardiac amyloidosis. [PDF]
Berrios-Bárcenas EA +21 more
europepmc +1 more source
[Prevalence of oral anticoagulation and quality of its management in primary healthcare: A study by the Health Sentinel Network of the Region of Valencia (Spain)]. [PDF]
Boned-Ombuena A +6 more
europepmc +1 more source
[Cardiovascular preventive recommendations. PAPPS 2024 thematic updates]. [PDF]
Orozco-Beltrán D +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Semergen, 2018
Direct oral anticoagulants have demonstrated efficacy and safety in the treatment of venous thromboembolic disease. A review is presented of the results of direct oral anticoagulants in the published clinical trials of extended anticoagulant treatment (after the first 3-6 months of treatment) of venous thromboembolic disease.
J M Calvo Romero
exaly +2 more sources
Direct oral anticoagulants have demonstrated efficacy and safety in the treatment of venous thromboembolic disease. A review is presented of the results of direct oral anticoagulants in the published clinical trials of extended anticoagulant treatment (after the first 3-6 months of treatment) of venous thromboembolic disease.
J M Calvo Romero
exaly +2 more sources
EMC - Tratado De Medicina, 2016
En este articulo se detallan los datos de la farmacologia de los anticoagulantes orales que permiten comprender las ventajas y los inconvenientes de las dos familias principales: las antivitaminas K (AVK) y los anticoagulantes orales directos (AOD), antifactor X activado (Xa) o antitrombinas directas. El inicio del tratamiento se simplifico con los AOD
E Pautas
exaly +2 more sources
En este articulo se detallan los datos de la farmacologia de los anticoagulantes orales que permiten comprender las ventajas y los inconvenientes de las dos familias principales: las antivitaminas K (AVK) y los anticoagulantes orales directos (AOD), antifactor X activado (Xa) o antitrombinas directas. El inicio del tratamiento se simplifico con los AOD
E Pautas
exaly +2 more sources
Anticoagulantes orales directos: puesta al día
Medicina Clínica, 2018Resumen Durante medio siglo los antagonistas de la vitamina K han sido la unica opcion disponible para la terapia anticoagulante oral. En los ultimos anos se han desarrollado anticoagulantes orales directos: un inhibidor directo de la trombina (dabigatran etexilato) y 3 inhibidores directos del factor X activado (rivaroxaban, apixaban y edoxaban ...
Ana Isabel Franco Moreno +2 more
exaly +2 more sources

